Sanofi Crushed Its Quarter — So Why Are Investors Running for the Exit?

Shares of Sanofi sank 6.8% to $41.82 today even after the French drugmaker posted a Q2 that cleared every hurdle Wall Street set. The disconnect tells a familiar pharma story: the present looks great, but the future just got murkier. The headline revenue beat and guidance upgrade failed to satisfy a market that had already priced in strong performance.

• The Numbers Were Excellent, and the Market Shrugged. Sanofi posted business operating income of €3.29 billion against analyst estimates of €2.96 billion, while revenue hit €11.60 billion versus estimates of €10.85 billion.

Dupixent, its blockbuster allergy and asthma drug, surged 37.6% to €5.2 billion — crossing €5 billion in a single quarter for the first time.

Management upgraded full-year 2026 guidance, now expecting sales growth of around 10% at constant currencies, up from a prior high-single-digit target. Yet none of it was enough to overcome what came next.

• The New CEO Is Gutting the Pipeline, and Investors Don't Yet See What Replaces It. Three drug programs were scrapped — amlitelimab, balinatunfib, and itepekimab — the same candidates behind last year's clinical failures. Amlitelimab alone was once touted as a $5 billion opportunity. CEO Belén Garijo, who took over in April from ousted predecessor Paul Hudson, launched a "very rigorous portfolio prioritization process" but offered no target number for further cuts, saying the strategic assessment is still ongoing.

Barclays analysts wrote that "some investors may have been hoping for a more significant strategic update," and that the lack of a "splash" plus pipeline cuts could offset any boost from the improved outlook.

• Dupixent Dependence Is the Elephant in the Room. Sanofi remains heavily reliant on Dupixent, which faces patent expiry in 2031 and potential biosimilar competition afterward.

Management now targets €25 billion in Dupixent sales by 2030, plus roughly €10 billion from newer drug launches. But with three pipeline candidates just axed and R&D spending jumping 17.9%, the math on diversifying before the patent cliff gets harder.

• A Leadership Overhaul Adds Uncertainty. Garijo replaced R&D chief Houman Ashrafian with former Roche executive Paulo Fontoura , and she has an M&A budget approaching $30 billion to reshape the portfolio. That firepower is reassuring, but investors are being asked to trust a strategy that hasn't yet been fully articulated — a tough sell when the stock had rallied into earnings and the clock to 2031 keeps ticking.